Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2701 to 2750 of 3761 results for treatment

  1. MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

    HealthTech guidance
    Last updated
    5 July 2022
    View recommendations

    Sections for HTG275

  2. For people with moderate and severe alcohol dependence who have significant comorbid problems, is an intensive residential rehabilitation programme clinically and cost effective when compared with intensive community-based care?

    those with severe problems and complex comorbidities, do not benefit from treatment and/or lose contact with services. One common...

    Research recommendation
    Published
    9 June 2015

  3. Risk tools to identify risk of developing COAG and risk of sight loss:- What is the predictive value of risk tools for identifying people in the community who are atincreased risk of developing chronic open angle glaucoma (COAG) and identifying people with COAG who are at increased risk of sight loss?

    conversion to COAG is important for guiding decisions about monitoring, treatment and referral. However, current evidence on the...

    Research recommendation
    Published
    18 October 2018

  4. What methods can improve the identification of women at high risk of postpartum psychosis and reduce this risk?

    increased risk of mortality in both the woman and her baby. Prophylactic treatment can be effective for women who are known to be at...

    Research recommendation
    Published
    9 June 2015

  5. Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

    Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

    Evidence summary
    Published
    30 March 2016

  6. Dopamine: In people with acute heart failure, congestion and worsening renal function, does the addition of low‑dose dopamine to standard therapy lead to greater diuresis and renal protection compared with adding placebo to standard therapy?

    clinically and cost effective decongestion in people admitted to hospital for treatment of decompensated heart failure. The study should...

    Research recommendation
    Published
    16 December 2021

  7. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  8. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  9. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  10. Laparoscopic helium plasma coagulation for the treatment of endometriosis (IPG171)

    We have moved interventional procedures guidance 171 to become HealthTech guidance 112. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Laparoscopic gastric plication for the treatment of severe obesity (IPG432)

    Interventional procedures, IPG432 - Issued: November 2012 --> We have moved interventional procedures guidance 432 to become HealthTech guidance 293. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  13. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  14. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  15. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Withdrawn guidance

  16. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  17. Fertility: assessment and treatment for people with fertility problems (CG11)

    This guideline has been updated and replaced by NICE guideline CG156.

    Withdrawn guideline

  18. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    likely to do well with conventional treatment (such as R-CHOP) and which people may benefit from intensive treatment with,...

    Research recommendation
    Published
    25 August 2016

  19. Long-term safety of ovarian stimulation and ovulation induction for women:- Is there an association between ovulation induction or ovarian stimulation and adverse long-term (over 20 years) effects in women in the UK?

    significant long-term health issues, especially ovarian malignancy. Both treatments are common in the management of infertile women. The...

    Research recommendation
    Published
    9 June 2015

  20. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (HTG281)

    Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.

    HealthTech guidance
    Last updated
    6 July 2017
    View recommendations

    Sections for HTG281

  21. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

    HealthTech guidance
    Published
    10 July 2025
    View recommendations

    Sections for HTG754

  22. Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)

    Interventional procedures, IPG417 - Issued: January 2012 --> We have moved interventional procedures guidance 417 to become HealthTech guidance 280. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  23. Electrocautery cutting balloon treatment for pelviureteric junction obstruction (IPG324)

    Interventional procedures, IPG324 - Issued: December 2009 --> We have moved interventional procedures guidance 324 to become HealthTech guidance 205. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  24. Implanted vagus nerve stimulation for treatment-resistant depression (IPG679)

    We have moved interventional procedures guidance 679 to become HealthTech guidance 551. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  25. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

    Medtech innovation briefing
    Published
    21 February 2023

  26. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

    HealthTech guidance
    Last updated
    25 July 2023
    View recommendations

    Sections for HTG606

  27. Insertion of hydrogel keratoprosthesis (HTG42)

    Evidence-based recommendations on insertion of hydrogel keratoprosthesis. This involves putting an artificial cornea into place in a pocket made in the front part of the eye.

    HealthTech guidance
    Published
    23 June 2004
    View recommendations

    Sections for HTG42

  28. Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)

    NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .

    Medtech innovation briefing
    Published
    27 July 2018

  29. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Withdrawn guidance

  30. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .

    Medtech innovation briefing
    Published
    18 June 2020

  31. Individual versus group CBT for children and young people with social anxiety disorder:- What is the clinical and cost effectiveness of individual and group CBT for children and young people with social anxiety disorder?

    populations, however, indicate that individually-delivered treatments are associated with better treatment outcomes and are...

    Research recommendation
    Published
    9 June 2015

  32. Effectiveness of the progestogen-only pill, injectable progestogens, or progestogen implants in alleviating HMB:- How effective are the progestogen-only pill, injectable progestogens or progestogen implants in alleviating HMB?

    is important:- Many women use LNG-IUS as the first-line pharmacological treatment for HMB, but it is not acceptable to all women....

    Research recommendation
    Published
    14 November 2018

  33. In well-defined generalised anxiety disorder (GAD), what is the clinical and cost effectiveness of two cognitive behavioural therapy (CBT) based low-intensity interventions (CCBT and guided bibliotherapy) compared with a waiting-list control?

    explanatory notes(if applicable) Why this is important:- Psychological treatments are a recommended therapeutic option for people with...

    Research recommendation
    Published
    9 June 2015

  34. In well-defined panic disorder, what is the clinical and cost effectiveness of two cognitive behavioural therapy (CBT) based low-intensity interventions (CCBT and guided bibliotherapy) compared with a waiting-list control?

    explanatory notes(if applicable) Why this is important:- Psychological treatments are a recommended therapeutic option for people with...

    Research recommendation
    Published
    9 June 2015

  35. ORA G3 to measure corneal hysteresis (MIB150)

    NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .

    Medtech innovation briefing
    Published
    18 June 2018

  36. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Outcome) P: hospitalised people with COVID-19I: treatment with a combination of casirivimab and imdevimabC:• treatment in...

    Research recommendation
    Published
    21 October 2021

  37. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  38. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  39. Desflurane for maintenance of anaesthesia (ES41)

    Summary of the evidence on desflurane for maintenance of anaesthesia

    Evidence summary
    Published
    26 March 2024

  40. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guidance

  41. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  42. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

    Withdrawn guidance

  43. CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)

    NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .

    Medtech innovation briefing
    Last updated
    9 December 2016

  44. Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

    This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.

    Clinical guideline
    Published
    15 December 2010
    View recommendations

    Sections for CG112

  45. Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]

    Awaiting development Reference number: GID-TA11830 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

    In development Reference number: GID-TA11823 Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  48. Radially emitting laser fibre treatment of an anal fistula (IPG644)

    We have moved interventional procedures guidance 644 to become HealthTech guidance 505. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  49. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  50. Neonatal infection (early onset): antibiotics for prevention and treatment (CG149)

    This guidance has been updated and replaced by NICE guideline NG195.

    Withdrawn guideline